Durata Therapeutics

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Durata Therapeutics, Inc.
Industry Pharmaceutical industry
Fate Acquired by Actavis (now Allergan)
Founded 2009; 9 years ago (2009)
Defunct November 17, 2014; 3 years ago (November 17, 2014)
Headquarters Morristown, New Jersey

Durata Therapeutics was a clinical development stage company in the pharmaceutical industry which focused on the treatment of infections. On November 17, 2014, the company was acquired by Actavis (now Allergan) for $675 million.

History[edit]

On December 21, 2009, the company acquired Vicuron Pharmaceuticals and its drug candidate, dalbavancin, a long-acting semisynthetic lipoglycopeptide antibiotic, from Pfizer and commenced operations.[1]

On April 19, 2011, the company initiated Phase III studies of dalbavancin for intravenous (IV) treatment of acute bacterial skin and skin structure infections.[2]

In 2012, the company moved its global headquarters from Morristown to Chicago and received $2 million in tax credits.[3]

On November 17, 2014, the company was acquired by Actavis (now Allergan) for $675 million.[4]

References[edit]